INTELLIA THERAPEUTIC (NTLA) is drawing unusual attention today. Our newswire has captured 1 story on NTLA across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 38/100).
Intellia Therapeutics Inc. stock is moving today, with NTLA trading in a volatile session amid recent corporate activity and analyst commentary. The stock's movement follows a report of inducement grants issued by the company under Nasdaq Listing Rule 5635(c)(4), as well as a series of analyst actions and earnings results that have shaped investor sentiment. The stock has a market capitalization of $1.8 billion and a beta of 1.82, indicating higher volatility than the broader market.
Intellia Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4), a move that signals the company is incentivizing new hires or executives with equity compensation. This development was reported by StockTitan and comes amid a backdrop of recent financial activity. Earlier in the month, Intellia entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a move that provides financial flexibility without issuing new shares. The company also reported second-quarter earnings of $(0.80) per share, missing the estimated $(0.79), and revenue of $7.659 million, below the projected $13.904 million. Analysts have been active in recent weeks, with Evercore ISI Group upgrading the stock to Outperform and raising its price target to $24, while Citizens reiterated a Market Outperform rating with a $30 price target.
NTLA stock has traded between $7.95 and $28.25 over the past 52 weeks. The stock is currently unprofitable, with an earnings per share of -3.34 for the trailing twelve months. Revenue has grown by 12.6% in the same period. Short-term insider activity has been bearish, with four sales totaling $507,000 reported in the last 90 days. The most recent insider transaction was on August 24, 2026. The stock’s high beta of 1.82 suggests it is more sensitive to market movements than the average stock.
Investors will want to monitor any further analyst activity or corporate updates, as well as the company’s ability to meet future revenue and earnings expectations. No earnings date is currently scheduled for the near term.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement. The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing […]
INTELLIA THERAPEUTIC (NTLA) is drawing unusual attention today. Our newswire has captured 1 story on NTLA across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 38/100). The most recent driver: "Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?" (Yahoo Top).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of NTLA coverage reads 38/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on NTLA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier NTLA move explainers: 2026-09-08